anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The objective of this study was to know the prevalence and clinical-epidemiological characteristics of patients with chronic infection due to hepatitis D virus (HDV).
PATIENTS AND METHODS: A retrospective descriptive study was carried out on patients with HDV infection under follow-up in a hospital in 2023. All patients carrying HBsAg were tested for antibodies against HDV. HDV RNA detection was performed in all antibody-positive samples. The medical records were reviewed.
RESULTS: Of the 340 patients carrying HBsAg, 24 (7.1%) had anti-HDV antibodies, and 6 (25%) had detectable HDV RNA (chronic infection). The prevalence of chronic hepatitis in HBsAg carriers was 1.8%. All patients had a genotype 1 infection. Half of the patients were of African origin and 29.2% were Spanish. Of the 6 patients with chronic infection, 5 (83.3%) had cirrhosis and 2 (33.3%) had hepatocellular carcinoma. Half of the patients had some exacerbation of the disease during follow-up. Of the 18 patients without viremia, 2 (11.1%) presented cirrhosis (one recently diagnosed). The mean follow-up time of patients without viremia was 13.5 years.
CONCLUSIONS: The prevalence of chronic HDV hepatitis in our area is low and in all cases it presents as an advanced disease, with exacerbations during follow-up. Patients without viremia have probably resolved the infection, as viremia was not detected in any moment.
Acute respiratory infections are the fourth cause of hospitalization in elderly. Hospital admissions due to pneumonia range from the 1.1 and 4 per 1,000 patients, increasing with age. Hospitalization causes a decline in physical and functional status. Physical impairment involves a higher risk of disability and mortality in elderly people. Various studies have examined the impact of hospitalization in patients with respiratory pathology, and it has been shown that hospitalization implies a significant physical impairment in patients admitted for pneumonia showing that this deterioration increases with age. That highlights the need of interventions in order to reduce the impact of hospitalization. The objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients hospitalized due to pneumonia.
To solve the problem that the conventional technique predicts the exacerbation risk on the basis of biological information while resting, including while sleeping, and does not take biological information while on exertion into consideration, which makes it impossible to make sufficient prediction of the exacerbation risk.SOLUTION: An exacerbation risk prediction system 1 provided herein can predict the exacerbation risk of a patient P with respiratory disease. The exacerbation risk prediction system 1 comprises an acquisition unit, a storage unit, and a prediction unit. The acquisition unit acquires first information including biological information and patient information. The biological information is information on the patient P in exertion and at rest. The patient information is information on the patient P pertaining to the medical condition. The storage unit stores the first information. The prediction unit predicts the exacerbation risk on the basis of the first information.SELECTED DRAWING: Figure 1
Breast cancer is the most common malignancy in women. Chemotherapy with taxanes in patients with breast cancer causes some complications and neuropathy is one of the most frequent that is dose limiting and even may cause to stop the therapy. n-3 fatty acids have very significant role in improvement the function of the neurons.n-3 fatty acids decrease the demyelination and toxicities resulting from taxanes. They also lower the level of of the neurotoxic inflammatory agents. So,n-3 fatty acids improve the quality of life in this patients. 52 patients with invasive breast cancer will be randomized in a double-blind placebo-controlled manner to receive either 640 mg oil fish pearls( 54% DHA, 10% EPA) 3 times a day or placebo( corn oil pearls) for 3 months(during the chemotherapy with taxanes). Neuropathy (using EMG-NCV test)and the level of IL-1,IL-6, TNF-alpha, hs-crp and serum level of EPA and DHA fatty acids will be measured before chemotherapy with taxanes and at the end of the therapy (after 3 months).
Participants receive affect-based goals for the first 8-weeks. In addition to the standard mHealth intervention, participants engage in the SAVOR enhancement to augment the treatment effects of the affect-based goals condition. Participants then cross-over to receive intensity-based goals for the second 8-weeks.
The cell transition from an inflammatory phase to a subsequent proliferative phase is crucial for wound healing, yet the driving mechanism remains unclear. By profiling lncRNA expression changes during human skin wound healing and screening lncRNA functions, we identify SNHG26 as a pivotal regulator in keratinocyte progenitors underpinning this phase transition. Snhg26-deficient mice exhibit impaired wound repair characterized by delayed re-epithelization accompanied by exacerbated inflammation. Single-cell transcriptome analysis combined with gain-of-function and loss-of-function of SNHG26 in vitro and ex vivo reveals its specific role in facilitating inflammatory-to-proliferative state transition of keratinocyte progenitors. A mechanistic study unravels that SNHG26 interacts with and relocates the transcription factor ILF2 from inflammatory genomic loci, such as JUN, IL6, IL8, and CCL20, to the genomic locus of LAMB3. Collectively, our findings suggest that lncRNAs play cardinal roles in expediting tissue repair and regeneration and may constitute an invaluable reservoir of therapeutic targets in reparative medicine.
The aetiological mechanism of gestational diabetes mellitus (GDM) has still not been fully understood. The aim of this study was to explore the associations between functional genetic variants screened from a genome-wide association study (GWAS) and GDM risk among 554 GDM patients and 641 healthy controls in China. Functional analysis of single nucleotide polymorphisms (SNPs) positively associated with GDM was further performed. Univariate regression and multivariate logistic regression analyses were used to screen clinical risk factors, and a predictive nomogram model was established. After adjusting for age and prepregnancy BMI, rs9283638 was significantly associated with GDM susceptibility (P < 0.05). Moreover, an obvious interaction between rs9283638 and clinical variables was detected (Pinteraction < 0.05). Functional analysis confirmed that rs9283638 can regulate not only target gene transcription factor binding, but it also regulates the mRNA levels of SAMD7 (P < 0.05). The nomogram model constructed with the factors of age, FPG, 1hPG, 2hPG, HbA1c, TG and rs9283638 revealed an area under the ROC curve of 0.920 (95% CI 0.902-0.939). Decision curve analysis (DCA) suggested that the model had greater net clinical benefit. Conclusively, genetic variants can alter women's susceptibility to GDM by affecting the transcription of target genes. The predictive nomogram model constructed based on genetic and clinical variables can effectively distinguish individuals with different GDM risk factors.
A traditional Chinese medicine for treating ankylosing spondylitis is prepared from the following raw materials: 2-4g radix aconiti kusenzoffii, 2-4g raw kusnezoff monkshood root, 2-4g cassia bark, 4-6g radix angelicae pubescentis, 4-6g spina gleditsiae, 4-6g radix aconiti lateralis preparata, 8-12g radix clematidis, 4-6g carthamus tinctorius, 4-6g Chinese wild ginger, 4-6g tuberculate speranskia herb, 250-350g moxa and 450-550g ginger. The above medicines are ground into powder, the moxa is packaged independently, and the ginger is smashed into juice paste for use. A patient is advised to lie on the back, the powder is arranged at a spine uniformly, and is about 2cm in width and about 0.5cm in thickness, gauze is applied on the powder, the ginger juice paste is horizontally laid on the gauze, and the moxa is placed on the ginger juice paste and ignited to the extent that an affected part is flushing, the patient has a sense of warmth locally, and no burn is caused. The medicine is administrated for five times, once per day, as a treatment course, and a second treatment course can be continued after 10 days. The medicine has the characteristics that materials are easy to draw, and the medicine is simple to prepare, low in cost, good in practicability and the like. The medicine has a low harmful ingredient content, and no toxic or side effects. The medicine has effects of tonifying qi, nourishing blood, promoting blood circulation to remove blood stasis, tonifying a liver and a kidney, strengthening bones and muscles and dredging a governor meridian, and has a significant therapeutic effect.
Plaque is one of the main etiological factors in dental decay and the principal etiological factor for periodontal diseases. Although toothbrushes have greatly evolved, dexterity is still the key component to an efficient cleaning routine. The primary goal is to examine 60 participants to determine the efficacy of a new powered teeth cleaning device designed to bypass the variability of individual dexterity compared with manual toothbrushing.

This is a single-blind, randomized controlled trial. Sixty pediatric patients will be recruited for the study and randomized into treatment and control groups, subdivided into primary (20), mixed (20), and permanent dentition (20). Participants will be asked to abstain from brushing, flossing, gum or mouthwash use for 24 hours prior to the study visit. Plaque will be assessed using the Turesky Modification of the Quigley-Hein Plaque Index before and after a one-time brushing with the assigned study device. A soft tissue assessment will be conducted and intraoral photos taken pre- and post-brushing.
Despite the frequent use of therapies in acute bronchitis, encouraged by the over-the-counter availability in pharmacies, the evidence of their benefit is scarce, since only a few clinical trials have been published, with low sample sizes, poor methodological quality and mainly in children. The objective of this study is to compare the effectiveness of 3 symptomatic therapies (dextromethorphan, ipratropium and honey) associated with usual care and the usual care in adults with acute bronchitis. This will be a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough for less than three weeks as the main symptom, scoring ≥ 4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the following four groups: usual care, usual care + dextromethorphan 30 mg t.i.d., usual care + ipratropium bromide inhaler 20 µg 2 puffs t.i.d, or usual care + 30 mg (a spoonful) of honey t.i.d., all taken for up to 14 days. The exclusion criteria will be: pneumonia, criteria for hospital admission, pregnancy or lactation, concomitant pulmonary disease, associated significant comorbidity, allergy, intolerance or contraindication to any of the study drugs, admitted to a long-term residence, or inability to give informed consent. Sample: 668 patients. The primary outcome will be the number of days with moderate-severe cough in the intention-to-treat (ITT) population, i.e., the number of days from the randomisation visit until the last day the patient scores three or more in either daytime or nocturnal cough in the symptom diary. All patients will be given a symptom diary to be self-administered while symptoms are present. A second visit will be scheduled at day 2-3 for assessing evolution, with two more visits at days 15 and 29 for clinical assessment, evaluation of adverse effects, re-attendance and complications. Patients still with symptoms at day 29 will be called six weeks after the baseline visit.
PURPOSE: To determine the significance of depth of invasion as a predictor of recurrence and mortality in tongue and non-tongue early-stage oral cavity squamous cell carcinoma patients treated with surgery and no postoperative radiotherapy.
MATERIALS AND METHODS: 344 patients with oral cavity squamous cell carcinoma from 2005 to 2022 at a tertiary academic medical center were reviewed. Patients were included if they had newly diagnosed, previously untreated T1-T2N0 disease treated with surgery alone that was observed within a follow-up of 5 years. For each patient, anatomic site of oral cavity squamous cell carcinoma was categorized as either tongue or non-tongue. Cox proportional hazards regression analyses were performed to determine the association of depth of invasion with recurrence and mortality, with anatomic site, smoking status, and age at biopsy as covariates. Model assumptions were tested by statistical and graphical evaluation using Schoenfeld residuals.
RESULTS: Of 108 patients with T1-T2N0 disease, 78 (72.2 %) had tongue disease, and 30 (27.8 %) had non-tongue disease. Median follow-up was 18.2 months (range, 0.01-58.2 months). In the Cox proportional hazards models, with adjustment for anatomic site and other covariates, depth of invasion positively predicted recurrence (HR 1.16, 95 % CI: 1.01-1.32, p = 0.034) and death (HR 1.42, 95 % CI: 1.11-1.83, p = 0.006).
CONCLUSIONS: Depth of invasion is an independent predictor of recurrence and death across early-stage tongue and non-tongue squamous cell carcinoma. Therefore, depth of invasion may indicate a need for more aggressive treatment than surgery alone, such as postoperative radiotherapy, even in the absence of other adverse features on pathology within the early-stage population.
A stable horse-chestnut seed extract containing saponin, effective transcutaneously, is prepared by (a) extracting horse-chestnut seed material or (b) dissolving a dry extract of horse-chestnut seed material prepared by known methods, with a polar organic solvent, having a boiling point higher than water, and containing preferably not more than 5 and particularly 3 carbon atoms in the molecule, especially propylene glycol. Anhydrous horse-chestnut seed material may be extracted with anhydrous methanol at below 30 DEG  C. and preferably below 0 DEG  C. and the dry extract remaining after removal of the solvent is dissolved in a mixture of a monohydric alcohol with 2 to 3 carbon atoms and propylene glycol containing 20 to 40% water. Alternatively, dried and degreased horse-chestnut seeds may be extracted with the aforesaid solvent mixture.  Solvent mixtures which may be employed consist of (a) 1,2-propylene glycol, 1,3-butylene glycol, glycerol or beta pyridine carbinol with (b) aliphatic monohydric alcohol containing 2-5 carbon atoms, ketones with 2-5 C atoms and a chloromethane, e.g. methylene chloride or chloroform.  The liquid extracts may be used topically as a cosmetic, e.g. for wrinkled skin, or therapeutic preparation, e.g. for inflammatory conditions, e.g. rheumatism, ulcers and arthritis.
The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
The invention relates to an Amolops hainanensis antimicrobial peptide Hainanenin-1, and a gene, separation purification, chemical synthesis and application thereof, belonging to the technical field of biomedicine. The Hainanenin-1 is a small peptide containing heptatomic ring at the C terminal, which is prepared by the following steps: electrically stimulating Amolops hainanensis, collecting the skin secretion, centrifuging, freeze-drying, carrying out Sephadex column chromatography and RP-HPLC (reversed phase-high performance liquid chromatography), and purifying. The molecular weight of the Hainanenin-1 is 2278.90, and the isoelectric point is 9.50. The primary structure is phenylalanine-alanine-leucine-glycine-alanine-valine-threonine-lysine-leucine-leucine-proline-serine-leucine-leucine-cysteine-methionine-isoleucine-threonine-arginine-lysine-cysteine. The precursor gene for coding the Hainanenin-1 is composed of 320 nucleotides, and the part for coding the mature peptide is 139th-201st nucleotides. When being used for preparing therapeutic drugs for pathogenic microbe infectious diseases, the Hainanenin-1 has the characteristics of broad-spectrum antimicrobial activity and low hemolysis.
This invention defines novel compositions that can be used for clinical treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, namely aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clinical disorders addressed herein. Such carbonyl substances are cytotoxic and additionally serve to perpetuate and disseminate the inflammatory process. This invention defines use of compositions, the orally administered required primary agents of which are primary amine derivatives of benzoic acid capable of covalently reacting with the carbonyl substances. p-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small molecular weight, is water-soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed therapeutically effective amount of at least one required primary agent; (2) at least one required previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route; and (3) one or more additional orally consumed required co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents; so as to-produce an additive or synergistic physiological effect of an anti-inflammatory nature.
A secured and programmable medical dispenser is configured to distribute medicine according to a schedule. The secured and programmable medical dispenser has a dispenser body mechanically coupled to a dispenser lid with a locking solenoid. A pill tube is arranged within the dispenser body and further has an open pill tube proximal end and a pill tube distal end. A pill release rotary solenoid is attached to the pill tube distal end. A liquid tube is arranged within the dispenser body and further has an open liquid tube proximal end and a liquid tube distal end. A liquid release rotary solenoid is attached to the liquid tube distal end. A microcontroller is attached to the dispenser lid, communicatively coupled to the pill release rotary solenoid and the liquid release rotary solenoid.
Primary cutaneous lymphomas (PCLs) are defined as non-Hodgkin lymphomas presenting in the skin with no evidence of extracutaneous disease at the time of diagnosis. Primary cutaneous lymphomas include a heterogeneous group of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs). The different types of PCLs have highly characteristic clinical and histologic features, often a completely different clinical behavior and prognosis, and require a different type of treatment. Various studied in terms of the treatment and outcome of patients with different types of PCLs has been conducted in recent years. While the data of Chinese patients with PCLs are limited. Considering the different proportion of PCLs and limited treatment modalities in China, a nationwide multi-center prospective study is designed to summarize the current treatment status and outcome of patients.
The invention relates to non-spherical drug-loaded particles and a controlled release preparation of a lactyl polymer and preparation methods thereof. The non-spherical particles of polylactic-co-glycolic acid (PLGA) are prepared by using an emulsion-solvent volatilization method assisted by small molecule materials. The PLGA is used as raw material coated with at least one of the following hydrophobic drugs: all-trans retinoic acid, paclitaxel, epirubicin, camptothecin or roxithromycin, wherein the mass ratio of the hydrophobic drug to a lactyl polymer high polymer material is 1:4-40. The drug-loaded particles of the all-trans retinoic acid are prepared and subjected to in vitro drug release evaluation. The results show that the preparation method has the advantages of simple preparation process, good reproducibility, significantly increased drug loading amount and encapsulation efficiency relative to spherical particles, very good controlled-release effect, no hemolysis initiation and safety use. The novel carrier and preparation have a potential industrial production value in the field of long-circulating controlled release of the hydrophobic drugs.
Patient education was provided in 3 sessions via telerehabilitation method, and exercises were provided with virtual reality support. It was requested that the exercises be done in 6 sets (30 repetitions) every day. Participants were given a splint, exercise brochure, and exercise diary for use at night.
Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study.
PROBLEM TO BE SOLVED: To obtain the subject new compound having cysteine protease inhibitory action, and useful as a prophylactic/therapeutic agent for diseases including osteoporosis, rheumatism and Alzheimer's disease, immunosuppressive agent, inhibitor for diseases including apoptosis, carcino metastasis and cataractogenesis, or the like. SOLUTION: This new compound is a compound of formula I [R1 is a lower alkyl; Y is a lower alkylene; R2 is OH, a (substituted) aryl or aryl-lower alkoxy; Z is O, imino or a group of formula II; R3 is H, a lower alkyl, pyridyl, a group of formula III (m is 1-6) or the like; n is 1-3; the asterisked C denotes C with R-configuration, C with S-configuration or the like], e.g. (R)-3-(trans-4- isopropylcyclohexylcarbonylamino)-2-oxo-4-phenylbutyric acid ethyl ester. The compound of formula I is obtained by oxidation of a compound of formula IV in one of various solvents (e.g. methylene chloride) in the presence of an oxidizing agent (e.g. sodium hypochlorite, pyridinium dichromate) pref. at room temperature to 50 deg.C for one hour to one day.